OVARIAN CANCER

Clovis Oncology’s Rubraca® (Rucaparib) Significantly Improves Progression-Free Survival in First-line Maintenance Treatment in Women with Ovarian Cancer Regardless of Their Biomarker Status in Phase 3 ATHENA-MONO Trial

Retrieved on: 
Thursday, March 31, 2022
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, THE ATHENA CLINICAL TRIAL, OVARIAN CANCER, BIOMARKERS IN OVARIAN CANCER, RUBRACA (RUCAPARIB), CLOVIS ONCOLOGY

The ATHENA-MONO study demonstrates the role of rucaparib monotherapy in the first-line maintenance treatment setting for advanced ovarian cancer.

Key Points: 
  • The ATHENA-MONO study demonstrates the role of rucaparib monotherapy in the first-line maintenance treatment setting for advanced ovarian cancer.
  • ATHENA is a double-blind, placebo-controlled, Phase 3 trial of rucaparib in first-line ovarian cancer maintenance treatment.
  • In 2020, GLOBOCAN estimated 314,000 women received a new diagnosis of ovarian cancer and approximately 207,200 women died from ovarian cancer.
  • According to the NIH National Cancer Institute, more than 75% of women are diagnosed with ovarian cancer at an advanced stage.

Novocure Announces Last Patient Enrolled in Phase 3 Pivotal INNOVATE-3 Trial of Tumor Treating Fields in Ovarian Cancer

Retrieved on: 
Thursday, October 28, 2021
Oncology, Health, Clinical Trials, Research, Pharmaceutical, Science, Woman, Death, Stomach, Ovarian cancer, Pancreatic cancer, Chromosome, Data monitoring committee, Quality of life, Diagnosis, Recurrence, Neoplasm, LinkedIn, Prognosis, Cancer, Disease, Cell division, Fundamental, Survival, Mitosis, Physician, Twitter, Patient, Private Securities Litigation Reform Act, NASDAQ, Paclitaxel, Liver cancer, Large-cell lung carcinoma, European Network of Transmission System Operators for Electricity, U.S. Securities and Exchange Commission, Adult, Protein, Glioblastoma, Annual report, Forward-looking statement, Standard of care, Cytoplasm, DMC, COVID-19, Skin, Cell, Alternating electric field therapy, Cell death, Microtubule, Population, Toxicity, Incidence, Mesothelioma, Pharmaceutical industry, Medical imaging, Ovarian Cancer, Tumor Treating Fields, Novocure, OVARIAN CANCER, TUMOR TREATING FIELDS, NOVOCURE

Novocure (NASDAQ: NVCR) today announced that the final patient has been enrolled in phase 3 pivotal INNOVATE-3 trial evaluating the efficacy of Tumor Treating Fields (TTFields) together with paclitaxel for treatment of patients with platinum-resistant ovarian cancer.

Key Points: 
  • Novocure (NASDAQ: NVCR) today announced that the final patient has been enrolled in phase 3 pivotal INNOVATE-3 trial evaluating the efficacy of Tumor Treating Fields (TTFields) together with paclitaxel for treatment of patients with platinum-resistant ovarian cancer.
  • INNOVATE-3 is a randomized, open-label study which was designed to enroll 540 adult patients with recurrent, platinum-resist ovarian cancer.
  • In the U.S., ovarian cancer ranks fifth in cancer deaths among women, with approximately 24,000 women diagnosed each year.
  • Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer and ovarian cancer.

China NMPA Approves PARP Inhibitor Pamiparib for Patients with Previously Treated Advanced Ovarian Cancer

Retrieved on: 
Friday, May 7, 2021
Biotechnology, Health, Pharmaceutical, Clinical trials, Oncology, Oncology, Gynaecological cancer, PARP inhibitor, Ovarian cancer, Gynecologic oncology, Medical specialties, Health, Orphan drugs, Clinical medicine, Ovarian Cancer, Pamiparib, the Pamiparib Clinical Program, BeiGene, OVARIAN CANCER, PAMIPARIB, THE PAMIPARIB CLINICAL PROGRAM, BEIGENE

BeiGene will continue working to advance our broad, diverse pipeline and executing on our mission of expanding access to and improving affordability of impactful treatments for patients worldwide.\xe2\x80\x9d\n\xe2\x80\x9cWe are thrilled that pamiparib is the first PARP inhibitor approved in China for patients with both platinum-sensitive and platinum-resistant relapsed ovarian cancer.

Key Points: 
  • BeiGene will continue working to advance our broad, diverse pipeline and executing on our mission of expanding access to and improving affordability of impactful treatments for patients worldwide.\xe2\x80\x9d\n\xe2\x80\x9cWe are thrilled that pamiparib is the first PARP inhibitor approved in China for patients with both platinum-sensitive and platinum-resistant relapsed ovarian cancer.
  • \xe2\x80\x9cWe appreciate the patients and investigators who participated in this trial, and hope that pamiparib will become an important treatment option for patients in China with recurrent ovarian cancer.
  • The encouraging pivotal Phase 2 data demonstrated that pamiparib can provide clinically meaningful and durable responses for patients who are sensitive or resistant to platinum-based chemotherapy.
  • CA Cancer J Clin, 2016;66(2):115-132.\nv Jiang X, Tang H, Chen T. Epidemiology of gynecologic cancers in China.